Join A Study

Join A Study

The only way we will find a cure for Parkinson’s disease (PD) cure is through research. Your participation in research is critical to finding new treatments and improving life for the 10 million people living with Parkinson’s around the world.

Explore the different opportunities to get involved with Parkinson’s research.

LEARN MORE ABOUT OUR RESEARCH PRIORITIES

Current Open Studies

PD GENEration: Mapping the Future of Parkinson’s Disease

This national initiative offers genetic testing for clinically relevant Parkinson's-related genes and genetic counseling at no cost for people with Parkinson’s. Participation can be either in-person or from home.

Join a Study - PD GENEration

Parkinson’s Foundation Surveys

Through this initiative, we aim to advance Parkinson’s care through understanding the experiences of people living with this disease, care partners and healthcare workers —and widely sharing those experiences with the PD community.

Join a Study - Survey

TOPAZ Trial

People with Parkinson's have a higher risk of fractures. Help us find a solution. The TOPAZ study will test if a medicine called zoledronate can prevent fractures in people with PD. A team of doctors who are experts in bone health and PD are leading the study.

Join a Study - TOPAZ Trial

Become a Research Advocate

Help us make Parkinson’s research more efficient and effective. Our trained research advocates partner alongside scientists, industry and government on critical PD research studies.

Biogen's REASON Study

The REASON Study is evaluating an investigational drug targeting the LRRK2 gene. Mutations in the LRRK2 gene (which provides instructions for making LRRK2 protein) are known to be associated with PD. Research studies have shown that one of the reasons for PD may be having too much LRRK2 protein in the brain. The study drug is designed to potentially reduce how much LRRK2 is produced by blocking some of the genetic instructions to create this protein. This is a phase 1 study, meaning that the study will be evaluating the investigational drug's safety for the first time in humans.

Join a Study - Biogen REASON Study

Biogen’s LUMINARE Studies

The Luminare Studies are evaluating the safety and efficacy of a study drug, as compared to a placebo, to see if it may delay the progression of Parkinson’s in its early stages. The Luminare studies include two individual studies, LUMA and LIGHTHOUSE. While both evaluate the same study drug, they have different criteria for participation. All participants receive genetic testing (at no cost), results help determines whether you may qualify for LUMA or LIGHTHOUSE.

Nurse reviewing medication with patient

Orchestra Study

The Orchestra Study is exploring the use of an oral investigational drug for men and women with early-stage Parkinson’s disease. The aim of the study is to see whether the investigational drug known as UCB0599 can slow the progression of Parkinson’s, by preventing the abnormal clumping of alpha-synuclein, which is associated to the loss of neurons in the brain. This is a Phase 2 study, meaning that the study will evaluate the efficacy, safety, tolerability and activity of UCB0599 in the body over a period of time.

Doctor giving patient medication
Back to Top